Current Clinical Trials

Department: Oncology
Diagnosis: Hematology- Lymphoma
Principal Investigator: Lash MD, Bradley
Sponsor: CALGB
Indentifier #: NCT01286272
Title: CALGB 50904, A Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumumab, Bortezomib (NSC # 681239, IND # 58443) and Bendamustine in Patients With Untreated Follicular Lymphoma
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lash MD, Bradley
Sponsor: ECOG
Indentifier #: NCT01107626
Title: E5508, Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC
Department: Family Practice
Diagnosis: Infectious Disease
Principal Investigator: Mohyuddin M.D., Aliasghar
Sub-Investigator(s):
Sponsor: Pfizer
Indentifier #: NCT00665561
Title: An International, Multicenter, Prospective Observational Study Of The Safety Of Maraviroc Used With Optimized Background Therapy In Treatment-Experienced HIV-1 Infected Patients
Department: Oncology
Diagnosis: Gastrointestinal - Colon-Rectal
Principal Investigator: Lowry MD, Philip
Sponsor: CALGB
Indentifier #: NCT01150045
Title: CALGB 80702, A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients With Resected Stage III Colon Cancer
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lash MD, Bradley
Sub-Investigator(s):
Sponsor: ECOG
Indentifier #: NCT00828009
Title: E6508, A Phase II Study of L-BLP25 and Bevacizumab in Unresectable Stage IIIA and IIIB Non-Squamous Non-Small Cell Lung Cancer after Definitive Chemoradiation
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lash MD, Bradley
Sponsor: RTOG
Indentifier #: NCT01822496
Title: RTOG 1306, A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC)
Department: Oncology
Diagnosis: Gastrointestinal - Liver
Principal Investigator:
Sub-Investigator(s):
Sponsor: CALGB
Indentifier #: NCT01015833
Title: CALGB 80802, Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib In Patients with Advanced Hepatocellular Carcinoma (HCC)
Department: Oncology
Diagnosis: Miscellaneous
Principal Investigator: Lowry MD, Philip
Sponsor: INC
Title: INCB-MA-PV-401, PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC OR COMMUNITY CLINICAL PRACTICES (REVEAL)
Department: Cardiology
Diagnosis: Cardiac - Miscellaneous
Principal Investigator: Sporn M.D., Daniel
Sub-Investigator(s):
Sponsor: PLC
Indentifier #: NCT01456013
Title: A Study to Evaluate RenalGuard® System Safety & Efficacy When Compared With Standard Care in the Prevention of Contrast Induced NephRopathy in the SettinG of a Catheterization Laboratory
Department: Oncology
Diagnosis: Cancer Control
Principal Investigator: Lash MD, Bradley
Sponsor: CALGB
Indentifier #: NCT01333033
Title: CALGB 80803,Randomized Phase II Trial of PET Scan-directed Combined Modality Therapy in Esophageal Cancer